Show simple item record

dc.coverage.spatialMedellín de: Lat: 06 15 00 N degrees minutes Lat: 6.2500 decimal degrees Long: 075 36 00 W degrees minutes Long: -75.6000 decimal degreeseng
dc.creatorCardona-Arias, Jaiberth Antonio
dc.creatorLópez Carvajal, Liliana
dc.creatorTamayo Plata, Mery Patricia
dc.date.available2018-06-25T23:01:10Z
dc.date.issued2018-01-15
dc.identifier.urihttp://hdl.handle.net/10784/12418
dc.description.abstractBackground: Cutaneous leishmaniasis causes a high disease burden in Colombia, and available treatments present systemic toxicity, low patient compliance, contraindications, and high costs. Objective: To estimate the cost-effectiveness of thermotherapy versus Glucantime in patients with cutaneous leishmaniasis in Colombia. Methods: Cost-effectiveness study from an institutional perspective in 8,133 incident cases. Data on therapeutic efficacy and safety were included, calculating standard costs; the outcomes were disability adjusted life years (DALYs) and the number of patients cured. The information sources were the Colombian Public Health Surveillance System, disease burden studies, and one meta-analysis of controlled clinical trials. Incremental cost-effectiveness was determined, and uncertainty was evaluated with tornado diagrams and Monte Carlo simulations. Results: Thermotherapy would generate costs of US$ 501,621; the handling of adverse effects, US$ 29,224; and therapeutic failures, US$ 300,053. For Glucantime, these costs would be US$ 2,731,276, US$ 58,254, and US$ 406,298, respectively. With thermotherapy, the cost would be US$ 2,062 per DALY averted and US$ 69 per patient cured; with Glucantime, the cost would be US$ 4,241 per DALY averted and US$ 85 per patient cured. In Monte Carlo simulations, thermotherapy was the dominant strategy for DALYs averted in 67.9% of cases and highly cost-effective for patients cured in 72%. Conclusion: In Colombia, thermotherapy can be included as a cost-effective strategy for the management of cutaneous leishmaniasis. Its incorporation into clinical practice guidelines could represent savings of approximately US$ 10,488 per DALY averted and costs of US$ 116 per additional patient cured, compared to the use of Glucantime. These findings show the relevance of the incorporation of this treatment in our country and others with similar parasitological, clinical, and epidemiological patterns.spa
dc.language.isoengspa
dc.publisherUniversidad EAFITspa
dc.rightsinfo:eu-repo/semantics/openAccesseng
dc.subjectAnálisis costo-efectivospa
dc.subjectLeishmaniasis cutáneaspa
dc.subjectTermoterapiaspa
dc.subjectGluconato de antimonio sódicospa
dc.subjectColombiaspa
dc.titleComprehensive economic evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Colombiaspa
dc.typeworkingPaperspa
dc.rights.accessRightsopenAccessspa
dc.publisher.departmentEscuela de Economía y Finanzasspa
dc.type.spaDocumento de trabajo de investigaciónspa
dc.subject.keywordCost-effectiveness evaluationspa
dc.subject.keywordCutaneous leishmaniasisspa
dc.subject.keywordThermotherapyspa
dc.subject.keywordSodium antimony gluconatespa
dc.subject.keywordColombiaspa
dc.rights.accesoLibre accesospa
dc.date.accessioned2018-06-25T23:01:10Z
dc.type.hasVersiondrafspa
dc.contributor.eafitauthorjaiberthcardona@gmail.cospa
dc.contributor.eafitauthorlililopez14@gmail.comspa
dc.contributor.eafitauthormptamayo@eafit.edu.cospa
dc.contributor.eafitauthorcspa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record